India’s Dr. Reddy’s Laboratories, which has been whiplashed repeatedly by FDA actions against its plants, saw its sales in the U.S. fall markedly in the last…
Rocked by a corruption scandal in Korea, Novartis is working to strengthen and simplify its global ethics and compliance approach.
The CFDA aims to speed orphan meds to market with conditional OKs for drugs approved abroad, even without any in-China trial data.
Generic drug companies, as well as their branded counterparts, worked through a tumultuous year in 2016.
Wockhardt reported a widened Q4 loss, Takeda penned a T-cell platform deal, and the FDA approved Mitsubishi’s ALS drug Radicava.
A U.S. generics manufacturing site that India’s Lupin picked up in its 2015 buyout of GAVIS Pharmaceuticals has now been significantly expanded as the…
Takeda’s plan to launch a Hib vaccine in Japan has ended in smoke as GlaxoSmithKline has terminated production of Vaxem Hib.
The FDA has warned Vikshara Trading & Investments for its repeated efforts to keep inspectors from getting a look into its filthy plant.
The FDA has cited an Aurobindo sterile manufacturing plant in India for not doing everything it can to prevent contamination, according to a new report.
India’s Wockhardt saw its losses widen last year as its burgeoning regulatory issues with the FDA continue to chainsaw away at its finances.